Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial
2022; European Respiratory Society; Volume: 59; Issue: 3 Linguagem: Inglês
10.1183/13993003.03036-2021
ISSN1399-3003
AutoresÀlvar Agustí, Gastón De Stéfano, Alberto Levi, Xavier Muñoz, Christian Romero‐Mesones, Oriol Sibila, Alejandra López-Giraldo, Vicente Plaza, Elena Curto, Andrés L. Echazarreta, Silvana Elizabeth Marquez, Sergi Pascual-Guàrdia, Salud Santos, Alicia Marín, Luís Valdés, Fernando Saldarini, Clara Salgado, Georgina Casanovas, Sara Varea, José Ríos, Rosa Faner,
Tópico(s)SARS-CoV-2 and COVID-19 Research
ResumoSARS-CoV-2 vaccines have been extremely effective in reducing the incidence of severe coronavirus disease 2019 (COVID-19) [1, 2], but effective and safe treatments for acute infection are still limited [3, 4]. An uncontrolled pulmonary inflammatory response to SARS-CoV-2 is considered a key pathogenic mechanism of COVID-19 progression [5], so systemic dexamethasone is recommended in severe cases [4, 6]. On the other hand, in very mild patients at home, inhaled corticosteroids (ICS) may prevent disease progression [7–10]. Whether ICS can also prevent disease progression in patients hospitalised because of COVID-19 has not been explored previously. Accordingly, we designed an investigator-initiated, open-label, randomised clinical trial (RCT) to explore the efficacy of adding inhaled budesonide to usual care to prevent disease progression in patients hospitalised because of COVID-19 pneumonia. We also carefully monitored the safety of this intervention since there are concerns about the use of systemic corticosteroids in other viral (influenza) lung infections [11]. The addition of inhaled budesonide to usual care is safe and may reduce the risk of disease progression in patients hospitalised because of COVID-19 pneumonia Authors thank all participants in the study for their willingness to contribute to medical research, and the Barcelona Respiratory Network ([www.brn.cat][1]) for facilitating collaborative research. We also acknowledge the support of the Clinical Trial Unit (L. Aparicio, J.A. Arnaiz), the Medical Statistics Core Facility (F. Torres, G. Domenech) of IDIBAPS-Hospital Clinic Barcelona in Spain, the members of the DSMB (B. Cosio, J.M. Miro, F. Barbe, F. Torres) as well as Klixar in Argentina (F. Licastro), for their support during the conduct of the trial and analysis of results. Finally, we acknowledge the economic and logistic support of AstraZeneca (Ana Perez and Gonzalo de Miquel). [1]: http://www.brn.cat
Referência(s)